{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:02:30Z","timestamp":1790920950942,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2434,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1002\/hep.22634","type":"journal-article","created":{"date-parts":[[2008,9,18]],"date-time":"2008-09-18T17:43:36Z","timestamp":1221759816000},"page":"50-59","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Complex dynamics of hepatitis B virus resistance to adefovir\u2020"],"prefix":"10.1097","volume":"49","author":[{"given":"Coralie","family":"Pallier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozenn","family":"Brillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Nordmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"H\u00e9zode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Michel","family":"Pawlotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20241201","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/135965350400900522","article-title":"Management of antiviral resistance in patients with chronic hepatitis B","volume":"9","author":"Locarnini","year":"2004","journal-title":"Antivir Ther"},{"key":"R2-9-20241201","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hep.21698","article-title":"Antiviral drug\u2010resistant HBV: standardization of nomenclature and assays and recommendations for management","volume":"46","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R3-9-20241201","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2006.01.001","article-title":"HBV drug resistance: mechanisms, detection and interpretation","volume":"44","author":"Shaw","year":"2006","journal-title":"J Hepatol"},{"key":"R4-9-20241201","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1053\/j.gastro.2007.11.036","article-title":"Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach","volume":"134","author":"Pawlotsky","year":"2008","journal-title":"Gastroenterology"},{"key":"R5-9-20241201","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S1386-6532(05)80021-6","article-title":"The concept of hepatitis B virus mutant escape","volume":"34","author":"Pawlotsky","year":"2005","journal-title":"J Clin Virol"},{"key":"R6-9-20241201","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long\u2010term therapy with adefovir dipivoxil for HBeAg\u2010negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"R7-9-20241201","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2002.34740","article-title":"Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks","volume":"36","author":"Yang","year":"2002","journal-title":"Hepatology"},{"key":"R8-9-20241201","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0016-5085(03)00939-9","article-title":"Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase","volume":"125","author":"Angus","year":"2003","journal-title":"Gastroenterology"},{"key":"R9-9-20241201","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/jhep.2003.50288","article-title":"Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B","volume":"38","author":"Westland","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R10-9-20241201","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2003.09.022","article-title":"Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient","volume":"39","author":"Villeneuve","year":"2003","journal-title":"J Hepatol"},{"key":"R11-9-20241201","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/JVI.80.2.643-653.2006","article-title":"Dynamics of hepatitis B virus resistance to lamivudine","volume":"80","author":"Pallier","year":"2006","journal-title":"J Virol"},{"key":"R12-9-20241201","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2006.11.016","article-title":"Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient","volume":"46","author":"Villet","year":"2007","journal-title":"J Hepatol"},{"key":"R13-9-20241201","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2006.08.013","article-title":"Selection of a multiple drug\u2010resistant hepatitis B virus strain in a liver\u2010transplanted patient","volume":"131","author":"Villet","year":"2006","journal-title":"Gastroenterology"},{"key":"R14-9-20241201","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hep.510290119","article-title":"Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance","volume":"29","author":"Pichoud","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R15-9-20241201","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.510270628","article-title":"Identification and characterization of mutations in hepatitis B virus resistant to lamivudine","volume":"27","author":"Allen","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R16-9-20241201","doi-asserted-by":"crossref","first-page":"11833","DOI":"10.1128\/JVI.77.21.11833-11841.2003","article-title":"The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro","volume":"77","author":"Delaney","year":"2003","journal-title":"J Virol"},{"key":"R17-9-20241201","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0006-2952(98)00050-1","article-title":"Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(\u2010)SddC (3TC) resistance","volume":"55","author":"Fu","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"R18-9-20241201","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/jhep.2002.35070","article-title":"Inhibitory activity of dioxolane purine analogs on wild\u2010type and lamivudine\u2010resistant mutants of hepadnaviruses","volume":"36","author":"Seigneres","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R19-9-20241201","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","article-title":"Entecavir resistance is rare in nucleoside naive patients with hepatitis B","volume":"44","author":"Colonno","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R20-9-20241201","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/S0168-8278(07)62379-4","article-title":"Four year assessment of entecavir resistance in nucleoside\u2010naive and lamivudine refractory patients","volume":"46","author":"Colonno","year":"2007","journal-title":"J Hepatol"},{"key":"R21-9-20241201","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1128\/AAC.48.9.3498-3507.2004","article-title":"Clinical emergence of entecavir\u2010resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine","volume":"48","author":"Tenney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-9-20241201","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1128\/AAC.00833-06","article-title":"Two\u2010year assessment of entecavir resistance in lamivudine\u2010refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present","volume":"51","author":"Tenney","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R23-9-20241201","first-page":"79","article-title":"Antiviral cross\u2010resistance between clinically important HBV mutants: phenotypic testing using the recombinant HBV\u2010baculovirus assay system","volume":"1","author":"Sozzi","year":"2005","journal-title":"Global Antiviral J"},{"key":"R24-9-20241201","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20723","article-title":"Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir","volume":"41","author":"Brunelle","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R25-9-20241201","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1128\/JCM.00272-07","article-title":"In vitro drug susceptibility analysis of hepatitis B virus clinical quasispecies populations","volume":"45","author":"Zhu","year":"2007","journal-title":"J Clin Microbiol"},{"key":"R26-9-20241201","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jhep.2007.01.018","article-title":"Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg\u2010positive patients with lamivudine\u2010resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily","volume":"46","author":"Hezode","year":"2007","journal-title":"J Hepatol"},{"key":"R27-9-20241201","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1074\/jbc.M708615200","article-title":"Multi\u2010level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination","volume":"283","author":"Truong","year":"2008","journal-title":"J Biol Chem"},{"key":"R28-9-20241201","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1053\/j.gastro.2007.08.079","article-title":"Low resistance to adefovir combined with lamivudine: a 3\u2010year study of 145 lamivudine\u2010resistant hepatitis B patients","volume":"133","author":"Lampertico","year":"2007","journal-title":"Gastroenterology"},{"key":"R29-9-20241201","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1177\/135965350601100801","article-title":"Unusual selection of rtA181V HBV mutants cross\u2010resistant to adefovir following prolonged lamivudine monotherapy: report of two cases","volume":"11","author":"Gerolami","year":"2006","journal-title":"Antivir Ther"},{"key":"R30-9-20241201","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/135965350701200509","article-title":"A novel mutation pattern emerging during lamivudine treatment shows cross\u2010resistance to adefovir dipivoxil treatment","volume":"12","author":"Karatayli","year":"2007","journal-title":"Antivir Ther"},{"key":"R31-9-20241201","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.20464","article-title":"Comparison of adefovir and tenofovir in the treatment of lamivudine\u2010resistant hepatitis B virus infection","volume":"40","author":"van Bommel","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R32-9-20241201","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.21253","article-title":"Tenofovir for patients with lamivudine\u2010resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy","volume":"44","author":"van Bommel","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R33-9-20241201","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"In vitro susceptibility of adefovir\u2010associated hepatitis B virus polymerase mutations to other antiviral agents","volume":"12","author":"Qi","year":"2007","journal-title":"Antivir Ther"},{"key":"R34-9-20241201","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2008.01.027","article-title":"Impact of hepatitis B virus rtA181V\/T mutants on hepatitis B treatment failure","volume":"48","author":"Villet","year":"2008","journal-title":"J Hepatol"},{"key":"R35-9-20241201","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jhep.2007.09.020","article-title":"Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir\u2010resistant mutations","volume":"48","author":"Tan","year":"2008","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22634","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200901000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:04:41Z","timestamp":1733058281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200901000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22634","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}